EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

David J Curtis iD, Sushrut S Patil, John Reynolds, Duncan Purtill, Clinton Lewis, David S Ritchie, David J Gottlieb, David T Yeung, Eric Wong, Siok-Keen Tey, Travis Perera, John Moore und 8 weitere

New England Journal of Medicine · 17.07.2025 · 393 (3) · 243-254

DOI: 10.1056/nejmoa2503189 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 17.07.2025. Verfasst von David J Curtis und 19 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Haematology, Alfred Health, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Cyclophosphamide, Cyclosporine, Graft vs Host Disease, Hematologic Neoplasms. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Australian Government, Cancer Society of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideCyclosporineGraft vs Host DiseaseHematologic NeoplasmsPeripheral Blood Stem Cell TransplantationAdultAgedFemaleHumansMaleMiddle AgedDisease-Free SurvivalDrug Therapy, CombinationImmunosuppressive AgentsKaplan-Meier EstimateMethotrexateTransplantation ConditioningTransplantation, HomologousCalcineurin InhibitorsNeoplasm Recurrence, Local

Substanzen

CyclophosphamideCyclosporineImmunosuppressive AgentsMethotrexateCalcineurin Inhibitors

Autor:innen und Institutionen

  • Clinical Haematology, Alfred Health, Melbourne, VIC, Australia.
  • Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
  • Haematology Service, Fiona Stanley Hospital-PathWest Laboratory Medicine, Perth, WA, Australia.
  • Haematology, Auckland City Hospital, Auckland, New Zealand.
  • Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney.

ORCID-Profile: David J Curtis

Förderung

  • NCI NIH HHS
  • Australian Government
  • Cancer Society of New Zealand
  • Auckland Medical Research Foundation
  • Department of Health and Aged Care, Australian Government

Zitieren

APA

Curtis, D. J., Patil, S. S., Reynolds, J., Purtill, D., Lewis, C., Ritchie, D. S., Gottlieb, D. J., Yeung, D. T., Wong, E., Tey, S. K., Perera, T., Moore, J., Koldej, R. M., De Abreu Lourenco, R., Stubbs, J., Morrissey, C. O., Munsef, N., Arenas, A., Hill, G. R., & Australasian Leukaemia and Lymphoma Group (2025). Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. New England Journal of Medicine, 393(3), 243-254. https://doi.org/10.1056/nejmoa2503189

Vancouver

Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, et al. Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. New England Journal of Medicine. 2025;393(3):243-254. doi:10.1056/nejmoa2503189

BibTeX
@article{Curtis2025,
  author = {Curtis, David J and Patil, Sushrut S and Reynolds, John and Purtill, Duncan and Lewis, Clinton and Ritchie, David S and Gottlieb, David J and Yeung, David T and Wong, Eric and Tey, Siok-Keen and Perera, Travis and Moore, John and Koldej, Rachel M and De Abreu Lourenco, Richard and Stubbs, John and Morrissey, C Orla and Munsef, Nadia and Arenas, Andrea and Hill, Geoffrey R and Australasian Leukaemia and Lymphoma Group, Australasian Leukaemia and Lymphoma Group},
  title = {Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {3},
  pages = {243--254},
  doi = {10.1056/nejmoa2503189}
}
Kostenlos starten →